Pulse of The Market: Tuesday’s 10 Worst Performers

Wall Street finished Tuesday’s trading in a lackluster fashion, with all major indices ending in the green territory, but only eking out small gains.

The tech-heavy Nasdaq rallied the most, up by 0.46 percent, followed by the S&P 500 with 0.16 percent, and the Dow Jones with a marginal 0.01 percent.

The muted trading spilled over into individual stocks, with 10 in particular posting significant losses. In this article, let’s explore the top 10 companies that performed poorly on Tuesday.

To come up with the list, we considered only the stocks with $2 billion market capitalization and $5 million in trading volume.

Source:Pexels

10. Uranium Energy Corp. (NYSEAMERICAN:UEC)

Uranium Energy dropped its share prices by 3.80 percent on Tuesday to close at $5.32 apiece as investors sold off positions to park funds amid the lack of fresh catalysts to buoy investing appetite.

Additionally, investor caution continues to linger for UEC amid the ongoing trade war between the United States and Canada.

As one of the largest uranium producers with operations in both countries, UEC stands to be hurt by higher import prices and possibly lower demand for uranium products.

Canada is currently the US’ largest uranium producer, delivering 27 percent of its total supply, followed by Australia and Kazakhstan with 22 percent of deliveries each, according to the US Energy Information Administration.

Late last month, a Canadian uranium miner and producer signaled that prices for US customers could rise by 10 percent if Trump’s tariff threats were to be implemented.

9. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals slashed its share prices by 3.83 percent on Tuesday to finish at $6.53 each amid the lackluster performance in the broader market that spilled over into its shares.

In recent news, RXRX welcomed the addition of Namandje Bumpus and Elaine Sun to the company’s board of directors.

Prior to her addition to the Board, Bumpus served as the Principal Deputy Commissioner for the Food and Drug Administration until December 31, 2024. She also has a distinguished background in scientific leadership roles, including her tenure as an endowed professor at Johns Hopkins University School of Medicine.

Meanwhile, Sun brings over 30 years of expertise in the life sciences and financial sectors. She currently serves as chief operating officer and chief financial officer at Mammoth Biosciences and holds senior positions at Halozyme Therapeutics and SutroVax.